Literature DB >> 16499250

Management of asthma: the essentials of good clinical practice.

N Aït-Khaled1, D A Enarson.   

Abstract

Asthma is a condition that affects all countries worldwide. It is a chronic, disabling condition that diminishes the quality of life and the economic prosperity of those who live with it. The majority of persons living with asthma are from developing countries. Asthma management necessitates long-term treatment that is expensive, making it less accessible to poor people. The cost of medications is the key factor preventing people living with asthma from having access to care that has the potential to relieve their suffering, improve their quality of life and enhance their economic status. Asthma is a disease caused by environmental exposures. Genetic factors predispose certain people to developing asthma once they are exposed to the causative agents, and certain factors can trigger symptomatic episodes of asthma in those who have already developed the disease. Certain clinical characteristics differentiate asthma from other chronic lung conditions. The most important of these is that the symptoms and functional disability caused by asthma vary from one occasion to another. In those with less severe asthma, they may be present on some occasions and not others; in those with more severe asthma, their degree of severity varies from one time to another.

Entities:  

Mesh:

Year:  2006        PMID: 16499250

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  2 in total

1.  Contribution of community pharmacists in educating the asthma patients.

Authors:  Hamoud Saud Alotaibi; Thippeswamy Boreddy Shivanandappa; Sivagurunathan Nagarethinam
Journal:  Saudi Pharm J       Date:  2015-06-15       Impact factor: 4.330

Review 2.  Asthma management in low and middle income countries: case for change.

Authors:  Kevin Mortimer; Helen K Reddel; Paulo M Pitrez; Eric D Bateman
Journal:  Eur Respir J       Date:  2022-09-15       Impact factor: 33.795

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.